Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE: Gefapixant for Refractory Chronic Cough
NCT06542484Phase 4Recruiting
- Sponsor
- Nagoya City University
- Start
- Dec 2024
- Primary completion
- Mar 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of difelikefalin in refractory chronic cough (RCC) and unexplained chronic cough, sponsored by Nagoya City University. Primary endpoint: Treatment satisfaction at 12 weeks. Started Dec 2024; status: recruiting.
02
Drugs
difelikefalin
03
Conditions
refractory chronic cough (RCC)unexplained chronic cough
Beyond the preview
Go deeper on NCT06542484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06542484.